Currently, the steroidal mineralocorticoid receptor antagonists (MRAs) including the first-generation spironolactone and the second-generation eplerenone are strongly recommended for patients with CKD and chronic heart failure (CHF) (Ponikowski et al., 2016; Pitt et al., 2017; Maddox et al., 2021). Here, NR3C2 is linked to chronic kidney disease.